Telix Pharmaceuticals (NASDAQ:TLX) Earns Outperform Rating from Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a report released on Wednesday, September 23rd, Benzinga reports. They presently have a $22.00 price objective on the stock. Wedbush’s target price points to a potential upside of 99.46% from the stock’s previous close.

Several other equities research analysts have also issued reports on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday, September 15th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $20.50.

Telix Pharmaceuticals Price Performance

Shares of TLX stock traded down $0.31 during trading hours on Wednesday, reaching $11.03. The stock had a trading volume of 74,761 shares, compared to its average volume of 225,538. The stock’s fifty day simple moving average is $11.38 and its 200 day simple moving average is $10.55. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $13.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the period. XY Capital Ltd purchased a new position in shares of Telix Pharmaceuticals in the first quarter worth about $120,000. Lazard Asset Management LLC lifted its stake in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after acquiring an additional 39,400 shares during the last quarter. Private Advisor Group LLC boosted its holdings in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares during the period. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals during the 2nd quarter valued at about $1,731,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.